The Department of Veterans Affairs announced its first-ever clinical trial evaluating psilocybin as a treatment for major depression in veterans on Aug. 5, including those with co-occurring post-traumatic stress disorder, the agency said. The trial is authorized under a memorandum of understanding between VA and HHS on psychedelic-assisted therapy research, VA said.
Psilocybin, the active compound in psychedelic mushrooms, remains a Schedule I controlled substance under federal law, making the VA trial one of the first federally authorized clinical studies of its use in a veteran population.
The decision to formally test psilocybin represents a significant departure from decades of federal drug scheduling policy. VA’s involvement lends institutional credibility to a field of research that has grown rapidly at academic institutions, where studies have shown psilocybin may provide rapid and sustained relief for treatment-resistant depression.
For veterans struggling with mental health conditions that have not responded to conventional treatments, the trial opens a potential new therapeutic pathway. An estimated 17 veterans die by suicide each day, according to VA data, and treatment-resistant depression is a significant risk factor for suicide.
Standard treatments for veteran depression and PTSD include antidepressant medications, cognitive behavioral therapy, and prolonged exposure therapy. While effective for many patients, these approaches fail to achieve remission for a substantial minority, leaving a population with few remaining options.
The trial adds to a growing body of research suggesting psilocybin may work through different neurological mechanisms than traditional antidepressants, potentially resetting brain connectivity patterns associated with depression. Academic institutions including Johns Hopkins University and New York University have published promising results from civilian trials.
VA did not disclose the number of participants, trial locations, or expected timeline for results. The trial’s design and oversight will involve VA’s Office of Research and Development and is subject to standard clinical trial protocols including informed consent and institutional review board approval.